Breast Implant — Cost, Top Hospitals & Success Rates | MyMedicPlus

Breast implant surgery involves the surgical placement of a medical-grade device — either silicone gel-filled or saline-filled — within the breast to increase size, restore volume, or reconstruct the breast following mastectomy. It is performed under general anaesthesia by a board-certified plastic or reconstructive surgeon and typically takes 60 to 90 minutes as a day-case procedure. Breast implants are among the most extensively studied medical devices globally, with safety monitoring registries in the US, EU, UK, and Australia providing decade-long outcome data.

Silicone implants consist of an outer silicone elastomer shell filled with cohesive silicone gel. Modern fifth-generation implants use cross-linked cohesive gel that maintains its shape and significantly reduces the risk of leakage compared with earlier liquid silicone designs. Saline implants consist of the same outer shell filled with sterile saltwater and are inflated to the desired volume during surgery. Both types come in a range of profiles (low, moderate, high, ultra-high), shapes (round, anatomical/teardrop), and surfaces (smooth, micro-textured, macro-textured).

The surgical technique involves creating a pocket either above (subglandular) or below (submuscular or dual-plane) the pectoralis major chest muscle, placing the implant within the pocket, and closing the incision. The choice of pocket and implant characteristics are individualised based on the patient's body measurements, tissue thickness, desired outcome, and the surgeon's assessment. Implant placement is typically a single procedure, though revision surgery may be needed during the patient's lifetime for complications or preference changes.

Cosmetically, breast implants are placed in women with hypomastia (small breast volume relative to body proportions), post-partum breast volume loss, significant weight-loss-related ptosis and volume depletion, and congenital breast asymmetry. The goal is to achieve a proportionate, natural-appearing breast contour that matches the patient's individual body and aesthetic goals.

Reconstructively, breast implants are placed as part of post-mastectomy breast reconstruction. Immediate reconstruction (implant placed at the time of mastectomy) or delayed reconstruction (months or years after mastectomy) can be performed. Two-stage reconstruction with a tissue expander followed by implant exchange is the most common approach in post-mastectomy reconstruction, allowing the skin envelope to be gradually expanded before final implant placement. Direct-to-implant reconstruction (one-stage) is possible in selected patients with favourable anatomy and skin quality. Implants are also used in gender-affirming surgery for transgender women as part of feminising procedures.

Ideal candidates for cosmetic breast implant surgery are women aged 18 or older (22 or older for silicone in some countries) with good overall health, non-smokers or willing to stop smoking well before surgery, and stable body weight for at least six months. Candidates should have realistic expectations and be motivated by personal desire. Women who plan future pregnancies should understand that pregnancy and breastfeeding can alter implant results, though implants do not impair fertility or contraindicate pregnancy.

Contraindications include active infection anywhere in the body, untreated breast cancer, silicone allergy (rare), autoimmune diseases with a high capsular contracture risk (relative), and major psychiatric conditions including severe body dysmorphic disorder. Patients who are very underweight with minimal breast tissue have increased risk of visible implant edges and should discuss fat grafting as an adjunct or alternative. Patients with significantly ptotic breasts require mastopexy (breast lift) combined with implant placement for an optimal result.

Silicone gel implants dominate worldwide owing to their natural feel, low rippling rate, and high patient satisfaction. Cohesive gel (gummy bear) implants — particularly anatomical shaped forms — provide excellent long-term shape but require precise pocket creation to prevent rotation. Round smooth silicone implants are the most popular globally and are simpler to place than shaped implants with no rotation risk. Saline implants are preferred by some surgeons for the ability to adjust intraoperative fill volume and are the only implant approved for patients under 22 in the US.

Pocket placement determines the natural appearance and complication profile. Subglandular placement gives immediate result with natural movement but has higher capsular contracture rates (10 to 25%) and more visible implant edges in thin patients. Submuscular placement provides better coverage with lower contracture rates (3 to 8%) and more natural look in thin patients, at the cost of slightly longer recovery and potential animation deformity with muscle contraction. Dual-plane placement combines benefits of both — the upper pole of the implant is under the muscle while the lower pole is subglandular — and is currently the most popular technique for cosmetic augmentation. Incision choices include inframammary fold (most versatile), periareolar (less visible but higher nerve risk), and transaxillary (armpit, no breast scar).

Patient satisfaction with breast implant surgery is consistently high, with 90 to 95% of patients reporting satisfaction in longitudinal studies. Improvements in breast volume, projection, and symmetry are immediate and durable. Psychological benefits including improved body image, sexual self-confidence, and quality of life are well documented. Reconstructive patients report significant improvements in body satisfaction and psychological wellbeing after post-mastectomy implant reconstruction.

Implant longevity has improved substantially with each device generation. Fifth-generation cohesive silicone implants from major manufacturers (Allergan, Mentor, Sientra, Motiva) have ten-year capsular contracture rates of 5 to 12% and rupture rates of approximately 1% per year. Many patients go 15 to 20 years without requiring revision. Modern patient registries allow ongoing monitoring of device performance, providing reassurance about long-term safety.

Capsular contracture — the formation of a firm scar capsule that compresses the implant — is the most significant long-term complication, occurring in 5 to 20% of patients over 10 years and classified by Baker grades I to IV. Grades III and IV require surgical release (capsulotomy) or replacement. Implant malposition, bottoming out, and symmastia (implants touching centrally) are technical complications managed with revision surgery. Sensory changes in the nipple and breast skin affect 7 to 15% of patients and are usually temporary but can rarely be permanent.

BIA-ALCL (breast implant-associated anaplastic large cell lymphoma) is a rare T-cell lymphoma found in the capsule around textured implants, with an estimated incidence of 1 in 2,500 to 1 in 25,000 textured implant placements. It typically presents as late unilateral seroma or a capsular mass. Most cases are effectively treated with capsulectomy and implant removal. This risk has led many surgeons and regulatory agencies to recommend smooth implants as the preferred option. Systemic silicone-related symptoms are not supported by level-one evidence of causation.

Post-operative recovery involves wearing a surgical support bra continuously for three to six weeks. Pain is managed with oral analgesia and is typically mild to moderate for the first week. Most patients can return to sedentary work within five to seven days. Driving is restricted until arm movement is comfortable, usually one to two weeks. Upper body exercise and heavy lifting are avoided for four to six weeks. Final implant settling (the implant softening and dropping into its final position) takes three to six months.

Long-term follow-up includes annual check-ups with the placing surgeon or a plastic surgeon, and MRI surveillance every two to three years as recommended by the FDA for silicone implants to screen for silent rupture. Patients should promptly report any new breast swelling, firmness, pain, or asymmetry. All patients should continue standard breast cancer screening (annual mammography after age 40), informing the radiographer about their implants so displacement views are taken. Patients travelling abroad for implant surgery should receive all device documentation (implant card with manufacturer, model, and serial number) to present to future healthcare providers.

Breast implant surgery in the United States costs $6,000 to $12,000 for cosmetic augmentation, covering surgeon fees, operating room, anaesthesia, and implants. Reconstructive implant surgery after mastectomy is typically covered by insurance (mandated by the Women's Health and Cancer Rights Act in the US). In the UK under private care, cosmetic augmentation costs £5,000 to £9,000; reconstructive implant procedures are covered by the NHS for post-mastectomy patients.

Medical tourism for breast implant surgery is well-established in Thailand, Turkey, Poland, and Mexico. Board-certified surgeons at accredited hospitals in Thailand charge $3,000 to $5,000 all-inclusive with CE-marked or FDA-cleared implants. Turkey offers similar quality for $2,500 to $4,000. Patients save 40 to 60% versus UK or US private rates. It is essential to receive the implant identification card at the time of surgery, confirming the device brand, model, and serial number — this documentation is required for any future revision, surveillance imaging, or reporting to device registries.

Autologous fat transfer (lipofilling) is the primary implant-free alternative for breast augmentation, using liposuction-harvested fat that is purified and injected into the breast. It provides a modest natural volume increase (typically one cup size), natural feel, no implant-related risks, and is permanent where fat survives (40 to 80% retention). It requires adequate donor fat reserves and may need multiple sessions to achieve the desired result. It cannot match the volume increase achievable with implants for patients seeking larger augmentation.

External vacuum devices (BRAVA system) claim to gradually expand breast tissue non-surgically but have shown very modest and temporary results in clinical studies and are not widely recommended. Hormonal approaches to breast enlargement are not evidence-based. For women seeking primarily improved breast shape and projection without volume increase, mastopexy (breast lift) addresses ptosis without implants. The optimal approach depends on the patient's anatomy, desired outcome, and tolerance of implant-related long-term monitoring requirements.